Publishable Summary for 22HLT06 GenomeMET
Metrology for genomic profiling to support early cancer detection and precision medicine

Overview

Cancer is a major burden on European society. Advances in genomics, driven by technologies such as Next Generation Sequencing (NGS) are transforming cancer care, enabling earlier and more accurate diagnosis, guiding therapy selection and driving development of targeted therapies (precision medicine), which improves patient outcomes and health system effectiveness. However, the quality and comparability of genomic profiling currently varies significantly and development of standards and metrological means to support the field are in their infancy. This project aims to address these needs by applying metrological principles to develop reference measurement systems (RMS) to support cancer genomic diagnostics in compliance with the In-vitro Diagnostic Device Regulation (IVDR EU 2017/746).

Need

Cancer is one of the most significant challenges for European societies and healthcare systems, being the second largest cause of death with more than 1.9 million deaths per year. Horizon Europe's Mission on Cancer has identified earlier diagnosis and implementation of precision medicine as key priorities for reducing deaths, improving health and the cost-effectiveness of health systems.

Precision medicine relies on molecular characterisation of a patient's disease, with genomic profiling central to new treatment models, enabling earlier and more accurate diagnosis/stratification and guiding targeted therapies. The EU Beating Cancer plan recommends genomic profiling for all cancer patients, with the "Cancer Diagnostic and Treatment for All" initiative improving access to new genomic diagnostics.

High quality genomic testing using technologies such as NGS and liquid biopsies is vital for successful implementation of precision medicine. However, NGS relies on complex multi-step workflows to simultaneously analyse large numbers of genomic variants. These are susceptible to major and poorly understood sources of uncertainty, resulting in significant variability and a current lack of comparability thereby impacting patient care and hindering wider implementation.

The standards and RMS to support assay validation and Quality Assurance (QA), including reference measurement procedures (RMP) and higher order methods, i.e., high-accuracy methods with low uncertainty that can be used as reference methods or for value assignment of reference materials, SI-traceable reference materials (RM) and measurement uncertainty (MU) guidance have yet to be established and are urgently needed to support new test development and approval under IVDR EU 2017/746 and implementation by clinical laboratories accredited to quality standards such as ISO 15189 or ISO 17025.

Developing and establishing novel metrological concepts, capabilities and RMS for genomic profiling will require a large-scale, multi-disciplinary and coordinated approach in collaboration with key end-user stakeholders to achieve the collective goals.

Objectives

The overall objective of this project is to develop metrological capability and to establish metrology frameworks to improve quality and reproducibility of critical processes within genomic profiling workflows as well as RMS

Report Status:
PU – Public, fully open

Publishable Summary

Issued: September 2023

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EURAMET. Neither the European Union nor the granting authority can be held responsible for them.

The project has received funding from the European Partnership on Metrology, co-financed from the European Union's Horizon Europe Research and Innovation Programme and by the Participating States.

for high accuracy SI-traceable cancer gene measurement to improve comparability and support assay validation as required by the IVDR (EU) 2017/746.

The specific objectives are:

1. To demonstrate the application of Reference Measurement Systems (RMS) to support development, validation, and quality assurance (QA) and external quality assessment (EQA) of genomic IVDs in accordance with EU IVDR 2017/746, including i) the establishment of an initial baseline framework (using outcomes from Objectives 2, 3 and 4), and ii) demonstration of proof of concept using key cancer genomic profiling models (NGS).
2. To establish Reference Measurement Procedures (RMPs) for high accuracy (VCs < 20 %) SI-traceable (to N=1) measurement of key cancer biomarkers and higher order methods to measure critical Quality Control (QC) parameters within genomic profiling workflows to support genomic RMS development.
3. To develop and characterise Reference Materials (RM) and external quality assessment (EQA) materials for genomic profiling in line with ISO 15194, ISO 15711 and JCTLM, with SI-traceable reference values and sequencing datasets, and to use these to establish a framework for SI traceable value assignment and commutability assessment of reference and EQA materials to support genomic IVDs.
4. To develop a framework for determining the measurement uncertainty (MU) in quantitative genomic data and nominal output data in multiparametric genomic profiles.
5. To facilitate take up of the measurement infrastructure, methods and materials developed in the project by the measurement supply chain (via EMN TLM), standards developing organisations (e.g., CEN TC 140 and ISO TC 212), and end users (e.g., healthcare, and medical laboratories, IVD developers, genomics/cancer/pathology institutes, EQA providers, RM producers, instrument/reagent developers, regulators).

Progress beyond the state of the art and results

GenomeMET will progress the state of the art by initiating development of novel metrological concepts, RMS and standards needed to support analytical validation and QA of genomic profiling IVDs for cancer patients. This will help enable implementation of accurate, comparable, and traceable genomic profiling for improved diagnosis, targeted treatment, and management of cancer. This will include:

Objective 1: To develop and demonstrate the application of Reference Measurement Systems (RMS) to support development, validation, and quality assurance of genomic IVD.

Global and European efforts are underway to develop guidelines and standards to support the validation and QA/EQA of genomic profiling. However, current guidance for genomic test validation and QA lacks routes for independent comparability and assessment of analytical performance criteria. This project will develop traceable methods for assessing critical quality attributes of key NGS genomic profiling workflow steps such as NA isolation (yield and quality) from clinical samples (tissue and liquid biopsy from lung and colorectal cancer (CRC) patients) and NGS library preparation (yield and uniformity of coverage) feeding into frameworks to support assay QA.

Objective 2: To establish reference Measurement Procedures (RMP) for cancer biomarkers, and higher order methods.

To date, there is only one primary RMP for quantification of a single cancer genetic variant in JCTLM DB, which is limited in scope to synthetic DNA controls. The project will develop RMPs for high accuracy and SI-traceable measurements of key cancer biomarkers, assessment of the performance of RMPs using contrived RMs as well as demonstrating the applicability of RMPs to support validation of genomic profiling workflows. It will also establish novel sequencing (NGS/Sanger) strategies/capabilities for orthogonal validation of genomic variant calls, and identity and purity certification of genomic RM/EQA materials.

Objective 3: To establish SI-traceable frameworks for the development and characterisation of Reference Materials (RMs) and EQA materials for genomic profiling.

WHO International Standards and commercial contrived RM/QCMs are only available for selected individual cancer biomarkers. Higher order RMs currently only exist for germline materials and only sequence identity is certified. In addition, these materials lack traceability to higher order standards and may not be commutable

because frameworks for assessing the commutability of genomic RMs have not yet been established. This project will support the roll-out of improved/new EQA schemes for cancer genomic profiling through provision of reference values to support traceability and comparability across schemes. It will establish routes for assessing commutability of complex multi-analyte genomic RMs taking into consideration nominal (variant identity) and quantitative Variant Allele Frequency (vAF) properties and will develop novel cell/tissue-based RM formats.

Objective 4: To develop a framework for determining measurement uncertainty (MU) of genomic profiling

Traditional MU approaches for clinical chemistry and genetic testing focuses on single analytes which are incongruent with multiparametric genomic testing. This project will establish a robust framework using statistical approaches for assessing MU for multi-parametric genomic profiling assays considering both quantitative (read count and vAF) and qualitative (sequence/variant identity) parameters.

Outcomes and impact

Outcomes for industrial and other user communities

This project's outcomes support the implementation of precision medicine for cancer patients. It is envisaged that these will have impacts across multiple key stakeholder communities including, but not limited to:

- IVD developers - RMS will support the generation of enhanced performance validation data incorporating MU and metrological traceability, enabling genomic IVD developers to better demonstrate performance in line with the IVDR. This will lead to improved quality and comparability of IVDs and faster translation to market through more streamlined and consistent regulatory submissions.

- Clinical laboratories – Higher order methods and QC materials for monitoring key workflow quality metrics and performance will enable clinical laboratories to establish improved and standardised QA frameworks, resulting in better quality and more comparable genomic profiling across laboratories and supporting accreditation (ISO 15189 or 17025)

- Healthcare providers – Frameworks for assessing analytical performance will enable healthcare providers to undertake improved Health Technology Assessments (HTA) of novel genomic IVDs, incorporating more robust data with defined uncertainties to support future test performance specifications and uptake of genomic profiling into health practice.

- RM producers – Frameworks for improved characterisation and SI-traceable value assignment of genomic RMs will enable RM producers to demonstrate metrological traceability and commutability in line with the IVDR and ISO 17511, leading to more streamlined RM development and a wider range of high quality RMs.

- EQA providers – Provision of SI-traceable reference values will enable EQA providers to demonstrate long term comparability and traceability of EQA materials and schemes, reducing reliance on arbitrary consensus values. This will improve robustness and quality of genomic EQAs, and support development of new schemes and harmonisation of EQAs in molecular pathology.

- Drug developers will be able to undertake more streamlined development of targeted therapies through improved quality of genomic data from clinical trials, enabling more accurate selection of responders/non responders, leading to reduced development times, fewer failures, lower costs, and more effective cancer therapies.

- Clinical researchers will be able to generate more robust, reliable and reproducible genomic datasets, helping to address the current reproducibility crisis in clinical translational research, supporting faster translation of novel biomarkers to the clinic.

- Regulators – RMS and guidance for assay validation, incorporating metrological traceability, will inform IVD competent authorities /regulators / reference laboratories on performance metrics for genomic profiling assays, enabling more streamlined assessment of new IVDs and development of recommendations for implementation of genomic approaches in clinical practice.

Outcomes for the metrology and scientific communities

This project will provide a vehicle for joint activity, inter-laboratory comparisons, and knowledge sharing to support development of novel metrological concepts and capability for clinical genomics. Outcomes will

support improved EU metrology infrastructure enabling provision of new RMS and measurement/calibration services allowing NMI/DIs to provide more reliable SI-traceable reference values and improving agreement between different laboratories worldwide. Outcomes include:

- Improved NMI/DI capabilities for quantification of cancer genomic biomarkers, quantification of total Nucleic acids and detection of panels of genomic variants, demonstrated through inter-laboratory comparisons.
- Dissemination of case studies to advance development of metrological frameworks for multi-analyte clinical genomic profiling.
- Submission of new RMP for quantification of cancer genomic biomarkers and SI-traceable RMs to JCTLM database.

The metrological capabilities developed in this project will also support the wider clinical genomics sector (e.g., rare diseases and non-invasive prenatal testing (NIPT)) where Next Generation Sequencing (NGS) profiling is being applied and complement metrology development for other 'omics sectors where multi parametric testing is needed, e.g., transcriptomics, proteomics, and metabolomics.

Outcomes for relevant standards

The RMS to support assay validation will enable IVD developers, clinical laboratories, and other end-users, e.g., EQA providers and RMs producers, to better comply with regulations and standards in the IVD field e.g., IVDR and ISO 15189, ISO 17025 and ISO 17511 through generation of more robust and comparable datasets incorporating metrological traceability and MU.

Higher order methods, i.e., high-accuracy methods with low uncertainty that can be used as reference methods or for value assignment of reference materials, e.g., dPCR and materials (RMs/EQA materials) will support stakeholder-driven standardisation initiatives, linked to GenomeMET, e.g., INSTAND-NGS4P project by providing the underpinning methods/materials required to assess performance.

Outputs from this project will be incorporated into relevant CEN TC 140 and ISO TC 212 standards in development for NGS and liquid biopsies through participant representation on drafting committees, and into periodic revisions of standards such as ISO 15193, ISO 15194 and ISO 20914.

Finally, proposals for new standards under CEN TC 140 or ISO TC 212 are expected during the lifetime of the project in order to support improved validation and QA of genomic profiling and accurate quantification of cancer gene biomarkers.

Longer-term economic, social and environmental impacts

Outputs from the project will support earlier cancer detection and implementation of precision medicine, through confident and valid uptake of genomic profiling. Cancer is the second largest cause of death in Europe, with more than 3.7 million new cases and 1.9 million deaths each year and carries an economic burden of €141.8 billion/pa (1.07 % of GDP). Earlier detection and genomics-guided targeted therapies with greater efficacy and less toxicity compared to traditional systemic therapies will significantly reduce healthcare costs and improve patient outcomes. High quality genomic testing will result in fewer diagnostic errors e.g., missed/incorrect diagnosis and support provision of the "right drug to the right patient at the right time" reducing the economic burden of cancer and allowing citizens to live longer and healthier lives.

The project's outputs will also support growth of the European IVD and oncology therapeutics markets, valued at 33 billion Euros/pa and 75 billion Euros/pa respectively, through more streamlined routes for approval of new companion and precision genomic diagnostics, and improved genomic data from clinical trials resulting in more accurate selection of responders and more streamlined development of novel targeted therapies.

Environmental impacts include a reduction in the use of medical tools/devices and diagnostic kits/ components through more accurate "right first time" testing. These components are often single-use plastic products, the disposal of which presents an environmental risk.

List of publications

-

This list is also available here: https://www.euramet.org/repository/research-publications-repository-link/

Project start date and duration:		1 September 2023, 36 months
Coordinator: Carla Divieto, INRIM Tel: +390113919971 E-mail: c.divieto@inrim.it Project website address: -		
Internal Beneficiaries: 1. INRIM, Italy 2. LNE, France 3. NIB, Slovenia 4. PTB, Germany 5. TUBITAK, Türkiye	External Beneficiaries: 6. CEA, France 7. FPO, Italy 8. INSTAND, Germany 9. MUG, Austria 10. UNITO, Italy	Unfunded Beneficiaries: -
Associated Partners: 11. BIO-RAD, United States 12. GenQA, United Kingdom 13. LGC, United Kingdom 14. METAS, Switzerland 15. MHRA, United Kingdom 16. ULE, United Kingdom		